Rare Diseases & Environmental Impact: Defining Low-Incidence Conditions & Sustainability

Low-incidence ailments (rare diseases) affect fewer than 200,000 people in the US (Orphan Drug Act definition) or <1 in 2,000 in the EU. Collectively, they impact ~30 million Americans.

Categories

• Genetic: Cystic fibrosis, Huntington's, muscular dystrophies (~80% of rare diseases)
• Rare cancers: Mesothelioma, adrenal cortical carcinoma, pediatric cancers
• Infectious: Prion diseases, rare tropical diseases in non-endemic areas
• Autoimmune/Inflammatory: Stiff person syndrome, APS-1, CANDLE syndrome
• Metabolic: PKU, Gaucher, Niemann-Pick

Environmental Impact Considerations

Domain	Impact	Mitigation
Drug manufacturing	Complex synthesis, hazardous waste, cold chain	Green chemistry, continuous manufacturing
Orphan drug pricing	High cost → resource allocation ethics	Value-based pricing, global access agreements
Diagnostic odyssey	Repeated travel, tests, specialist visits	Telemedicine, newborn screening expansion, AI diagnostics
Medical waste	Specialized supplies (enzymes, biologics, devices)	Reusable systems, recycling programs
Clinical trials	Global travel for small populations	Decentralized trials, remote monitoring

Sustainability Frameworks

• Planetary Health: Rare disease care within ecological boundaries
• Circular Economy: Device reprocessing, packaging redesign
• Equity: Ensure environmental burden doesn't fall disproportionately on vulnerable populations

Rare diseases are not rare collectively. Their environmental footprint deserves attention alongside therapeutic innovation.